Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Reduced sensitivity of SARS-CoV-2 Omicron variant to booster-enhanced neutralization

Xiaoqi Yu, Dong Wei, Wenxin Xu, Yulong Li, Xinxin Li, Xinxin Zhang, Jieming Qu, Zhitao Yang, Erzhen Chen
doi: https://doi.org/10.1101/2021.12.17.21267961
Xiaoqi Yu
1Department of Infectious Diseases, Research Laboratory of Clinical Virology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dong Wei
1Department of Infectious Diseases, Research Laboratory of Clinical Virology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wenxin Xu
1Department of Infectious Diseases, Research Laboratory of Clinical Virology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yulong Li
1Department of Infectious Diseases, Research Laboratory of Clinical Virology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xinxin Li
1Department of Infectious Diseases, Research Laboratory of Clinical Virology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xinxin Zhang
1Department of Infectious Diseases, Research Laboratory of Clinical Virology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
2Clinical Research Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: zhangx@shsmu.edu.cn
Jieming Qu
3Department of Pulmonary and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
4Institute of Respiratory Diseases, Shanghai Jiao Tong University School of Medicine, Shanghai, China
5Shanghai Key Laboratory of Emergency Prevention, Diagnosis and Treatment of Respiratory Infectious Diseases, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhitao Yang
6Department of Emergency, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erzhen Chen
6Department of Emergency, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

The Omicron Variant of Concern (B.1.1.529) has spread internationally and is raising serious concerns about reduced vaccine efficacy and the increased risk of reinfection. We assessed the serum neutralizing activity using a pseudovirus-based neutralization assay in 292 healthcare workers who had received a homologous booster dose of BBIBP-CorV vaccine, 8 to 9 months after completing the priming two-dose vaccination schedule, to investigate whether the newly identified Omicron variant can escape serum antibody neutralization induced by the booster vaccination. The booster dose of BBIBP-CorV rapidly induced a significantly high level of humoral immune response, and the neutralization geometric mean titer (GMT) against the wild-type strain on day 28 after the booster dose was 294.85 (252.99-343.65), 6.1 times higher than the level on day 28 after the second dose. The neutralization against the Omicron variant was also improved by the booster vaccination, although the GMT showed an approximately 20.1-fold reduction to 14.66 (12.30-17.48) when compared with the wild-type strain. This study demonstrated that a booster dose of BBIBP-CorV led to a significant rebound in neutralizing immune response against SARS-CoV-2, while the Omicron variant showed partial resistance to neutralizing antibodies induced by the booster vaccination.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study was funded by Shanghai Key Laboratory of Emergency Prevention, Diagnosis and Treatment of Respiratory Infectious Diseases (20dz2261100), and a grant from Science and Technology Commission Shanghai Municipality (No. 20JC1410200).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethics Committee of Shanghai Ruijin Hospital gave ethical approval for this work (RJHKY2021-321)

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Data updated.

Data Availability

The data that support the findings of this study are available from the corresponding authors on reasonable request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted December 26, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Reduced sensitivity of SARS-CoV-2 Omicron variant to booster-enhanced neutralization
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Reduced sensitivity of SARS-CoV-2 Omicron variant to booster-enhanced neutralization
Xiaoqi Yu, Dong Wei, Wenxin Xu, Yulong Li, Xinxin Li, Xinxin Zhang, Jieming Qu, Zhitao Yang, Erzhen Chen
medRxiv 2021.12.17.21267961; doi: https://doi.org/10.1101/2021.12.17.21267961
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Reduced sensitivity of SARS-CoV-2 Omicron variant to booster-enhanced neutralization
Xiaoqi Yu, Dong Wei, Wenxin Xu, Yulong Li, Xinxin Li, Xinxin Zhang, Jieming Qu, Zhitao Yang, Erzhen Chen
medRxiv 2021.12.17.21267961; doi: https://doi.org/10.1101/2021.12.17.21267961

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (230)
  • Allergy and Immunology (507)
  • Anesthesia (111)
  • Cardiovascular Medicine (1264)
  • Dentistry and Oral Medicine (207)
  • Dermatology (148)
  • Emergency Medicine (283)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (538)
  • Epidemiology (10056)
  • Forensic Medicine (5)
  • Gastroenterology (502)
  • Genetic and Genomic Medicine (2486)
  • Geriatric Medicine (240)
  • Health Economics (482)
  • Health Informatics (1653)
  • Health Policy (757)
  • Health Systems and Quality Improvement (638)
  • Hematology (250)
  • HIV/AIDS (538)
  • Infectious Diseases (except HIV/AIDS) (11896)
  • Intensive Care and Critical Care Medicine (627)
  • Medical Education (255)
  • Medical Ethics (75)
  • Nephrology (269)
  • Neurology (2304)
  • Nursing (140)
  • Nutrition (354)
  • Obstetrics and Gynecology (458)
  • Occupational and Environmental Health (537)
  • Oncology (1259)
  • Ophthalmology (377)
  • Orthopedics (134)
  • Otolaryngology (226)
  • Pain Medicine (158)
  • Palliative Medicine (50)
  • Pathology (326)
  • Pediatrics (737)
  • Pharmacology and Therapeutics (315)
  • Primary Care Research (282)
  • Psychiatry and Clinical Psychology (2295)
  • Public and Global Health (4850)
  • Radiology and Imaging (846)
  • Rehabilitation Medicine and Physical Therapy (493)
  • Respiratory Medicine (657)
  • Rheumatology (289)
  • Sexual and Reproductive Health (241)
  • Sports Medicine (228)
  • Surgery (273)
  • Toxicology (44)
  • Transplantation (131)
  • Urology (100)